---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-020476"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T11:30:04.648864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma launches Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis, citing positive Phase 1b/2a data

## Summary
- Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.
- Phase 1b/2a data showed dose-dependent improvements; 5.0 mg/kg group had three patients completely taper off steroids.
- Efzofitimod demonstrated control of inflammatory biomarkers (IFN-γ, IL-6, IP-10, MCP-1, TNFa) over 24 weeks.
- Two higher doses (3.0 and 5.0 mg/kg) improved lung function measures (FVC, DLCO) vs placebo.
- Trial expected to initiate Q3 2022; Phase 1b/2a results presented at ATS 2022 conference May 17.

## SEC filing metadata
- accession: 0001564590-22-020476
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/0001564590-22-020476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/life-8k_20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-020476
- JSON: https://secwatch.observer/filing/0001564590-22-020476.json
- Plain text: https://secwatch.observer/filing/0001564590-22-020476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.